Tenaya Therapeutics, Inc. (TNYA): Price and Financial Metrics


Tenaya Therapeutics, Inc. (TNYA): $3.12

0.11 (+3.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TNYA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TNYA Stock Price Chart Interactive Chart >

Price chart for TNYA

TNYA Price/Volume Stats

Current price $3.12 52-week high $32.00
Prev. close $3.01 52-week low $2.77
Day low $3.05 Volume 37,787
Day high $3.23 Avg. volume 158,496
50-day MA $4.38 Dividend yield N/A
200-day MA $8.78 Market Cap 129.06M

Tenaya Therapeutics, Inc. (TNYA) Company Bio


Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.


TNYA Latest News Stream


Event/Time News Detail
Loading, please wait...

TNYA Latest Social Stream


Loading social stream, please wait...

View Full TNYA Social Stream

Latest TNYA News From Around the Web

Below are the latest news stories about TENAYA THERAPEUTICS INC that investors may wish to consider to help them evaluate TNYA as an investment opportunity.

Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions

Encore Presentation of Lead Gene Therapy TN-201 Preclinical Data to be Featured in Late-Breaking Trials SessionSOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that it is scheduled to participate in the Hypertrophic Cardiomyopathy Medical Society’s (HCMS)

Yahoo | September 29, 2022

Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that Faraz Ali, Chief Executive Officer, is scheduled to participate in the Chardan 6th Annual Genetic Medicines Conference and the Alliance for Regenerative Medicine’s Cell and Gene Meeting on the Mesa. Det

Yahoo | September 29, 2022

10 Best Biotech Stocks Under $10

In this article, we will look at the 10 best biotech stocks under $10. If you want to explore similar biotech stocks with promising prospects that you can get for under $10, you can also take a look at 5 Best Biotech Stocks Under $10. The Global Biotech Industry According to an industry analysis report […]

Yahoo | September 26, 2022

Harvard University’s Latest Portfolio: 10 Best Biotech Stock Picks

In this article, we will look at Harvard University’s latest stock portfolio and list its 10 best biotech stock picks. If you want to explore more biotech stocks that make up the top holdings of Harvard Management, you can also take a look at Harvard University’s Latest Portfolio: 5 Best Biotech Stock Picks. Harvard Management […]

Yahoo | September 15, 2022

H.C. Wainwright Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Tenaya Therapeutics (TNYA - Research Report) today and set a price target of $25.00. The company's shares opened today at $4.75.According to TipRanks, Pantginis is an analyst with an average return of -21.1% and a 27.68% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Humanigen, Astria Therapeutics, and Celldex.Tenaya Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $29.75.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $32.00 and a one-year low of $4.15. Currently, Tenaya Therapeutics has an average volume of 172.9K.

Carrie Williams on TipRanks | September 6, 2022

Read More 'TNYA' Stories Here

TNYA Price Returns

1-mo -31.58%
3-mo -45.26%
6-mo -76.47%
1-year -86.59%
3-year N/A
5-year N/A
YTD -83.54%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6406 seconds.